Equities research analysts expect Natera Inc (NASDAQ:NTRA) to post ($0.59) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Natera’s earnings, with estimates ranging from ($0.65) to ($0.52). Natera reported earnings per share of ($0.61) in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.3%. The firm is expected to report its next quarterly earnings results on Tuesday, May 14th.
On average, analysts expect that Natera will report full year earnings of ($2.24) per share for the current year, with EPS estimates ranging from ($2.39) to ($2.03). For the next financial year, analysts anticipate that the company will post earnings of ($1.51) per share, with EPS estimates ranging from ($1.85) to ($1.33). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Natera.
Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, March 12th. The medical research company reported ($0.51) EPS for the quarter, hitting analysts’ consensus estimates of ($0.51). Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. The firm had revenue of $67.00 million for the quarter, compared to analysts’ expectations of $62.87 million.
Shares of NTRA opened at $20.62 on Wednesday. The company has a current ratio of 2.11, a quick ratio of 1.99 and a debt-to-equity ratio of 2.28. Natera has a 52 week low of $8.60 and a 52 week high of $29.62. The company has a market capitalization of $1.25 billion, a PE ratio of -9.59 and a beta of 1.84.
In other Natera news, insider Matthew Rabinowitz sold 5,672 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $16.00, for a total transaction of $90,752.00. Following the completion of the sale, the insider now directly owns 1,288,853 shares in the company, valued at approximately $20,621,648. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 3,192 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $16.00, for a total transaction of $51,072.00. Following the sale, the chief financial officer now owns 13,422 shares of the company’s stock, valued at $214,752. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 348,079 shares of company stock valued at $7,066,729. 13.18% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in NTRA. Great West Life Assurance Co. Can raised its stake in Natera by 136.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after buying an additional 3,420 shares during the last quarter. Legal & General Group Plc raised its stake in Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after buying an additional 736 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in Natera during the 3rd quarter valued at $106,000. Point72 Hong Kong Ltd purchased a new stake in Natera during the 3rd quarter valued at $119,000. Finally, Quantbot Technologies LP purchased a new stake in Natera during the 3rd quarter valued at $135,000. Institutional investors and hedge funds own 88.22% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Compound Interest and Why It Matters When Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.